常规儿童狂犬病暴露前预防在低中收入国家可具成本效果
研究采用决策树模型,比较儿童常规狂犬病暴露前预防(PrEP)与仅使用暴露后预防(PEP)的增量成本效果比(ICER)。模型显示在多种暴露风险、PEP可及性、PrEP成本和效力组合下,ICER多低于1000美元/质量调整生命年(QALY);当PrEP效力超过50%且狂犬病发病率≥3/10万/年、疫苗成本≤5美元/儿童时,ICER低于500美元/QALY。作者结论为在支付意愿不高的地区常规儿童PrEP可能具成本效果。
要点
- 模型评估儿童常规PrEP对比仅用PEP的ICER,多数情景下低于1000美元/QALY。
- PrEP效力超过50%且发病率≥3/10万/年、成本≤5美元/儿童时,ICER低于500美元/QALY。
- 发病率约0.3/10万/年时,即使PrEP效力低至30%,ICER仍可能低于3000美元。
核心结论
- 在支付意愿不高的地区,常规儿童PrEP可能具成本效果,前提是采用低成本PrEP方案且PrEP对无法获得PEP者具有一定效力。
研究设计与样本
- 研究采用决策树模型,该模型此前用于支持Gavi对狂犬病PEP的投资决策,比较儿童常规PrEP与仅使用PEP的增量成本效果比(ICER)。
主要发现
- 在狂犬病暴露风险、PEP可及性、PrEP成本和PrEP效力的多种可能组合下,模型ICER均低于1000美元/QALY。
- 若PrEP在15年内效力超过50%,在狂犬病发病率≥3/10万/年且疫苗接种成本≤5美元/儿童时,估计ICER低于500美元/QALY。
- 在发病率约0.3/10万/年的较低情景下(因暴露有限或PEP可及性更高),即使PrEP效力低至30%,ICER仍可能低于3000美元。
关键数值与推荐
- PrEP效力超过50%(15年内)、狂犬病发病率≥3/10万/年、疫苗成本≤5美元/儿童时,ICER低于500美元/QALY。
- 狂犬病发病率约0.3/10万/年时,即使PrEP效力低至30%,ICER仍可能低于3000美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-exposure prophylactic rabies vaccination (PrEP) is advised for travellers to countries with high rabies incidence, but rarely available for local residents. Some studies suggest poor cost-effectiveness of PrEP in such settings, but have generally focused upon post-exposure prophylaxis (PEP) cost savings as the main benefit of PrEP, without considering lives saved by PrEP efficacy. METHODS: We compared incremental cost-effectiveness ratios (ICERs) of use of rabies PrEP, against an alternative of using only PEP, by adapting a decision-tree model previously used to inform Gavi's investment in rabies PEP. We consider scenarios including: a range of PrEP efficacies in individuals unable to access PEP; PrEP costs significantly below current prices (through single-dose approaches, inclusion in childhood vaccination schedules, increased manufacturing volume and/or new low-cost products); and variable rabies exposure risk and PEP access. We also present results from a simplified model, designed for ease of understanding. RESULTS: Modelled ICERs were <1000 USD per quality adjusted life year (QALY) across a range of plausible combinations of rabies exposure risk, PEP access, PrEP cost and PrEP efficacy. If PrEP efficacy exceeds 50 % over 15 years, we estimate ICERs <500 USD/QALY where rabies incidence ≥3 per 100,000 per year and cost of vaccination is ≤5 USD/child. Under scenarios with lower rabies incidence of around 0.3 per 100,000 per year, due either to more limited exposure or greater access to PEP, ICERs <3000 USD may still be achieved even if PrEP efficacy is as low as 30 %. CONCLUSIONS: Routine childhood PrEP may be cost-effective in settings with modest willingness-to-pay, and rabies exposure risks plausible across much of Africa and South Asia. Cost-effectiveness requires low-cost PrEP regimes and some efficacy of PrEP in individuals unable to access PEP. Under such conditions, PrEP may be an attractive additional tool in the fight against rabies.
引用
- Ritchie AJ, Meeyai A, Trotter C, et al. Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries. Vaccine. 2025. PMID: 39799849. doi:10.1016/j.vaccine.2024.126703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。